| 6.8702 0.01 (0.15%) | 12-05 10:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.93 |
1-year : | 9.97 |
| Resists | First : | 7.64 |
Second : | 8.53 |
| Pivot price | 6.7 |
|||
| Supports | First : | 6.19 | Second : | 5.15 |
| MAs | MA(5) : | 6.76 |
MA(20) : | 6.83 |
| MA(100) : | 7.9 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 47.6 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 11.55 | Low : | 5.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NVAX ] has closed below upper band by 35.8%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.88 - 6.9 | 6.9 - 6.93 |
| Low: | 6.66 - 6.69 | 6.69 - 6.72 |
| Close: | 6.81 - 6.85 | 6.85 - 6.91 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Tue, 25 Nov 2025
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Wed, 12 Nov 2025
Novavax to Participate in Jefferies London Healthcare Conference - PR Newswire
Tue, 11 Nov 2025
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thu, 06 Nov 2025
Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges - Yahoo Finance
Wed, 29 Oct 2025
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - Yahoo Finance
Wed, 08 Oct 2025
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 60.8 (%) |
| Shares Short | 50,680 (K) |
| Shares Short P.Month | 45,830 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.96 |
| Profit Margin | 32 % |
| Operating Margin | -112.7 % |
| Return on Assets (ttm) | 18 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -16.7 % |
| Gross Profit (p.s.) | 3.89 |
| Sales Per Share | 6.52 |
| EBITDA (p.s.) | 2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -378 (M) |
| Levered Free Cash Flow | -455 (M) |
| PE Ratio | 3.39 |
| PEG Ratio | 0 |
| Price to Book value | -7.12 |
| Price to Sales | 1.04 |
| Price to Cash Flow | -2.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|